Keywords: strong, ph, i/ii, data, osiris, chondrogen, usa

Strong Ph I/II data for Osiris' Chondrogen

Article | 19 February 2007

Print This

The USA's Osiris Therapeutics has reported strong six-month interim results from an evaluation of its stem-cell product Chondrogen for the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in